Click here to visit Company website

Agennix AG, a biopharmaceutical company, engages in developing therapies in the areas of unmet medical needs to improve the length and quality of life of seriously ill patients primarily in Germany and the United States. The company’s lead program, talactoferrin, is an oral targeted therapy in Phase III clinical development for the treatment of severe sepsis and non-small cell lung cancer.